They understand that phosphate retention as manifested by elevated FGF 23 may be as powerful predictor of cardiovascular disease as elevated cholesterol.

-- Within the Renal business, sales of sevelamer therapies Renagel(R)
(sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million
from $137.4 million in the first quarter last year. In March, Genzyme
launched Renvela in the United States, where the company is engaged in
active discussions with the FDA to expand the product's labeling to
include chronic kidney disease patients with hyperphosphatemia who are
not on dialysis. The three companies that currently market phosphate
binders are working collaboratively to provide the FDA with information
that will help the agency determine the appropriate treatment paradigm
for these patients. Genzyme anticipates that the Renvela label
expansion will take place at the latest by the middle of 2009. Genzyme
has also filed for European approval for Renvela in both the dialysis
and chronic kidney disease indications.

Published ahead of print on September 3, 2009
Journal of the American Society of Nephrology
© 2009 American Society of Nephrology
doi: 10.1681/ASN.2009050559 This Article

Full Text (Rapid PDF)
All Versions of this Article:
ASN.2009050559v1
20/11/2348 most recent
Alert me when this article is cited
Alert me if a correction is posted

Services

Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager


Google Scholar

Articles by Sabbagh, Y.
Articles by Schiavi, S. C.

PubMed

PubMed Citation
Articles by Sabbagh, Y.
Articles by Schiavi, S. C.



Received May 30, 2009
Accepted on July 1, 2009

--------------------------------------------------------------------------------

BASIC RESEARCH


Intestinal Npt2b Plays a Major Role in Phosphate Absorption and Homeostasis
Yves Sabbagh , Stephen P. O’Brien , Wenping Song , Joseph H. Boulanger , Adam Stockmann , Cynthia Arbeeny , and Susan C. Schiavi 1

Renal and Endocrine Sciences Group, Genzyme Corporation, Framingham, Massachusetts